A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets 5/2.5mg, 10/5mg, 20/10mg or 40/20mg Compared to Oxycodone PR 5mg, 10mg, 20mg or 40mg in Subjects With Moderate to Severe, Chronic Cancer Pain

Trial Profile

A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets 5/2.5mg, 10/5mg, 20/10mg or 40/20mg Compared to Oxycodone PR 5mg, 10mg, 20mg or 40mg in Subjects With Moderate to Severe, Chronic Cancer Pain

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2016

At a glance

  • Drugs Oxycodone/naloxone (Primary) ; Oxycodone
  • Indications Cancer pain
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 17 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 29 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top